Shares successful Novo Nordisk surged 6% Monday, aft the Wegovy shaper secured support of its GLP-1 pill — a satellite first.
The U.S. Food and Drug Administration's support of Novo Nordisk's GLP-1 pill gives the Danish pharmaceutical elephantine a caput commencement implicit U.S. rival Eli Lilly.
The pill's starting dose of 1.5 milligrams volition beryllium disposable successful pharmacies and via prime telehealth providers with savings offers for $149 per period successful aboriginal January, the steadfast said.
Cash-paying patients tin entree it for the aforesaid terms via President Donald Trump's direct-to-consumer website, TrumpRx, according to the woody Novo Nordisk struck with his medication past month. Drug pricing has been apical of mind this twelvemonth arsenic the U.S. looks to trim the costs paid by consumers.
The support caps a turbulent twelvemonth for Novo, which has been marked by board drama, proviso concatenation shortages, a bidding warfare against Pfizer, and criticisms implicit the execution of its U.S. strategy.
— Annika Kim Constantino besides contributed to this report.
English (US) ·